A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug. The studies presented a number of critical challenges to the PRA project team. Through teamwork and strategic planning, PRA developed plans that helped us reach the client’s milestones and resulted in successful site activations and first patient in.

You may also be interested in: